Real-life comparison of Nilotinib versus Dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
Crossref DOI link: https://doi.org/10.30574/gscbps.2025.33.2.0432
Published Online: 2025-11-30
Update policy: https://doi.org/10.30574/gscbps.ourcrossmarkpolicy
HABERROU, Wiam
BENBACHIR, Hamza
SEDDIKI, Manel
SULTAN, Badra ENTA
TOUMI, Houari
